Viking Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) announced participation in four investor conferences in September 2020. The events include the Citi's 15th Annual BioPharma Conference on September 9-10, Morgan Stanley Global Healthcare Conference on September 14-16, Cantor Fitzgerald Virtual Global Healthcare Conference from September 15-17, and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21-23. The Cantor Fitzgerald and Oppenheimer presentations will be available via webcast on the company's website. Viking is focused on developing therapies for metabolic and endocrine disorders.

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences. 

Details of the company's participation are as follows:

• Citi's 15^th Annual BioPharma Conference  
  Details: Viking management will participate in 1-on-1 meetings
  Conference Date: September 9-10, 2020
  Format: Virtual Conference
   
• Morgan Stanley Global Healthcare Conference
  Details: Viking management will participate in 1-on-1 meetings
  Conference Date: September 14-16, 2020 
  Format: Virtual Conference
   
• Cantor Fitzgerald Virtual Global Healthcare Conference
  Details: Viking management will deliver a corporate presentation (webcast available) and participate in 1-on-1 meetings 
  Conference Date: September 15-17, 2020
  Presentation Time/Date: 12:00 p.m. Eastern on Thursday, September 17, 2020 
  Format: Virtual Conference
   
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
  Details: Viking management will deliver a corporate presentation (webcast available) and participate in 1-on-1 meetings
  Conference Date: September 21-23, 2020
  Format: Virtual Conference

The Cantor Fitzgerald and Oppenheimer presentations will be webcast live and may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, replays of the webcasts will be available on the Viking website following the conferences. 

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).  The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301123211.html

SOURCE Viking Therapeutics, Inc.

FAQ

What investor conferences is Viking Therapeutics participating in September 2020?

Viking Therapeutics will participate in four conferences: Citi's BioPharma Conference (Sept 9-10), Morgan Stanley Global Healthcare Conference (Sept 14-16), Cantor Fitzgerald Healthcare Conference (Sept 15-17), and Oppenheimer Healthcare Summit (Sept 21-23).

Where can I watch the presentations from Viking Therapeutics' investor conferences?

Presentations from the Cantor Fitzgerald and Oppenheimer conferences will be webcast live and can be accessed on the Viking Therapeutics website.

What is the focus of Viking Therapeutics' research and development efforts?

Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders, including VK2809 for non-alcoholic steatohepatitis and VK0214 for X-linked adrenoleukodystrophy.

What is VK2809 being evaluated for in clinical trials?

VK2809 is being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.

What are the dates for the Cantor Fitzgerald Virtual Global Healthcare Conference?

The Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for September 15-17, 2020.